Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
NCT05819866Phase 3Active, not recruiting
- Sponsor
- Minoryx Therapeutics
- Start
- Jul 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in cerebral adrenoleukodystrophy (CALD) comparing Leriglitazone with Placebo (2 arms). Primary endpoint: Time to death or the subject becoming bedridden with a requirement for permanent ventilatory support at 36 months. Started Jul 2023; status: active, not recruiting.
02
Drugs
leriglitazone
03
Conditions
cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on NCT05819866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819866.